Delphia Therapeutics has appointed David Kerstein as its chief medical officer. Kerstein arrives with direct experience in the role, having previously served as CMO at both IDRx and Theseus Pharmaceuticals — a track record that matters in a seat where execution determines whether a drug program lives or dies.
What a Chief Medical Officer Actually Does
The CMO — chief medical officer — is the senior physician-executive who translates a company's scientific bets into clinical trial design and regulatory strategy. In a biotech, that job carries an outsized weight: clinical failures are the most common reason early-stage companies burn through their cash and shut down. The CMO decides how trials are structured, what endpoints regulators will accept, and when a program is ready to move forward or needs to be redesigned. Get it wrong and the company often does not get a second chance.
What Kerstein's Record Shows
Kerstein has held the CMO title at two prior companies — IDRx and Theseus Pharmaceuticals — before landing at Delphia. Cycling through CMO roles at multiple distinct biotechs is less routine than headlines make it seem. The pipeline of physicians willing to leave clinical practice or large-pharma stability for the concentrated risk of an emerging company is genuinely narrow, and executives who have navigated that environment more than once carry firsthand knowledge of what the role demands.
What the Hire Does Not Tell Us
The announcement specifies the appointment and Kerstein's background; it does not detail what clinical programs at Delphia he will oversee, what stage they have reached, or what timeline the company is working against. Those are the questions worth watching. An executive hire is a signal, not a guarantee — and the mechanism that actually matters here is what happens next in the clinic, not the press release.